Regeneron Pharma (REGN) PT Lifted to $490 at Roth Capital

Canaccord Genuity Raises PT of Regeneron Pharmaceuticals (REGN) to $525 from $460

Canaccord Genuity is reiterating their Buy rating on Regeneron Pharmaceuticals (NASDAQ: REGN), as well as raising the price target to $525 (from $460), after REGN posted strong 1Q15 sales. REGN reported sales of $541M, beating out both Street and Canaccord estimates of $527M and $522M. REGN guides are being conservative, estimating a gradual initial Praulent uptake.

Canaccord Genuity analyst, John Newman, commented on (REGN) saying, "The growth was driven primarily... More

Regeneron (REGN) PT Lifted to $507 at Brean Capital Amid Strong Eylea Sales

Brean Capital analyst Jonathan Aschoff reiterated a Buy rating and boosted his price target on Regeneron Pharma (NASDAQ: REGN) to $507.00 (from $450.00) following strong Q1 US Eylea sales.

Aschoff commented, "1Q15 US Eylea sales of $541 million beat consensus of $537 million. Sales growth comprised a 10% QoQ increase in underlying physician demand, offset by a modest QoQ decrease in inventory levels. Importantly, Regeneron raised its guidance for 2015 US Eylea sales... More

Regeneron Pharma (REGN) Estimates, PT Lifted at Piper Jaffray

Piper Jaffray analyst Edward Tenthoff raised his price target on Regeneron Pharma (NASDAQ: REGN) to $484.00 (from $415.00) following results but reiterated a Neutral rating.

Tenthoff commented, "U.S. EYLEA sales of $541 million in 1Q:15 topped our $534 million estimate and management increased 2015 sales growth... More

Regeneron (REGN) Tops Q1 EPS by 20c; Boosts U.S. EYLEA Sales Outlook

Regeneron (NASDAQ: REGN) reported Q1 EPS of $2.88, $0.20 better than the analyst estimate of $2.68. Revenue for the quarter came in at $870 million versus the consensus estimate of $820.3 million.

Net product sales were $545 million in the first quarter of 2015, compared to $362 million in the... More